BUSINESS
Japan Firms Joining Fray in siRNA Drug Development; Takeda Could File as Early as FY2025
By Tomohiro Osakabe June 6, 2023
R&D is picking up speed in the field of small interfering RNA (siRNA) therapies. What has been the stronghold of Alnylam Pharmaceuticals has now seen more developers moving into the arena. Among Japanese players, furthest…

LATEST

June 6, 2023
The Japanese government on June 2 issued a timeline for the promotion of digital transformation in healthcare, including a plan to build a national data platform that would enable sharing and exchanging information on health…
June 6, 2023
Sysmex said on June 5 that it has won Japanese regulatory approval for PrismGuide IRD Panel System, the first gene panel testing system for inherited retinal dystrophy (IRD) in the country. The clearance was granted on May 31.PrismGuide IRD, a…
June 6, 2023
Japan’s health ministry is expected to approve as early as September what would be the first cold medicines containing loxoprofen sodium hydrate in the country.The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) committee on nonprescription drugs on June 5 gave…
By Philip Carrigan

As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…

By Sakura Kono

Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…

By Tatsuya Otsuka

Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA